Targeting PCSK9 as a key player in lipid metabolism: exploiting the therapeutic and biosensing potential of aptamers

Abstract The degradation of low-density lipoprotein receptor (LDLR) is induced by proprotein convertase subtilisin/kexin type 9 (PCSK9), resulting in elevated plasma concentrations of LDL cholesterol. Therefore, inhibiting the interactions between PCSK9 and LDLR is a desirable therapeutic goal for m...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Maryam Mahjoubin-Tehran, Samaneh Rezaei, Raul D. Santos, Tannaz Jamialahmadi, Wael Almahmeed, Amirhossein Sahebkar
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	BMC 2024-05-01
Cyfres:	Lipids in Health and Disease
Pynciau:	Aptamer PCSK9 LDLR LDL Hypercholesterolemia
Mynediad Ar-lein:	https://doi.org/10.1186/s12944-024-02151-8
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!